~~<i id='DB3BCC82C1'><strike id='DB3BCC82C1'><tt id='DB3BCC82C1'><pre id='DB3BCC82C1'></pre></tt></strike></i>~~

Home» focus» hotspot

hotspot

author：explore 2025-09-28 12:03:11 Page View：616

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Congress must reauthorize a committee to support older Americans
Next article： What does generative AI mean for health care? We asked experts

Wikipedia

Malaria cases in Florida and Texas: Here’s what you need to know

MosquitoscaughtfortestingawaitshipmenttoalabinMcAllen,Texas,inApril2016tobetestedformosquito-bornedi

Biogen nominates mother of director’s child to replace him on board

StevenSenn/APBiogen,abiotechgiantplaguedbyyearsofboardroomstrife,saidlateMondaythatthelongtimeandpol

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

Weight loss drug costs may need more research, senator suggests

Sen.BillCassidy(R-La.)KevinDietsch/GettyImagesWASHINGTON—WithNovoNordisk’sWegovyandOzempichittingblo